Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia ,
, Blood, vol.120, issue.26, pp.5128-5133, 2012.
A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment, Blood, vol.120, issue.6, pp.1197-1201, 2012. ,
Mutations and prognosis in primary myelofibrosis, Leukemia, vol.27, issue.9, pp.1861-1869, 2013. ,
MIPSS70: mutationenhanced international prognostic score system for transplantationage patients with primary myelofibrosis, J Clin Oncol, vol.36, issue.4, pp.310-318, 2018. ,
Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms, Leukemia, vol.30, issue.2, pp.431-438, 2016. ,
Quantification of JAK2V617F mutation by next-generation sequencing technology, Am J Hematol, vol.88, issue.6, pp.536-537, 2013. ,
Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from european LeukemiaNet, J Clin Oncol, vol.29, issue.6, pp.761-770, 2011. ,
Mutation status of essential thrombocythemia and primary myelofibrosis defines clinical outcome, Haematologica, vol.101, issue.4, pp.129-132, 2016. ,
Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients, Blood, vol.127, issue.3, pp.333-342, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01258942
Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12 and TET2 in myeloproliferative neoplasms, Genes Chromosomes Cancer, vol.51, issue.8, pp.743-755, 2012. ,
Sequential analysis of 18 genes in polycythemia vera and essential thrombocythemia reveals an association between mutational status and clinical outcome, Genes Chromosomes Cancer, vol.56, issue.5, pp.354-362, 2017. ,
URL : https://hal.archives-ouvertes.fr/inserm-01500343
Age-related clonal hematopoiesis associated with adverse outcomes, N Engl J Med, vol.371, issue.26, pp.2488-2498, 2014. ,
Effect of mutation order on myeloproliferative neoplasms, N Engl J Med, vol.372, issue.7, pp.601-612, 2015. ,
Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis, Blood, vol.129, issue.24, pp.3227-3236, 2017. ,
Targeted deep sequencing in polycythemia vera and essential thrombocythemia, Blood Adv, vol.1, issue.1, pp.21-30, 2016. ,
Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms, Blood, vol.123, issue.14, pp.2220-2228, 2014. ,
Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms, Proc Natl Acad Sci, vol.111, issue.50, pp.5401-5410, 2014. ,
Impact of genotype on leukaemic transformation in polycythaemia vera and essential thrombocythaemia, Br J Haematol, vol.178, issue.5, pp.764-771, 2017. ,